Cytokinetics (CYTK) January calls and puts active
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq poised to lead Wall St after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Wall Street bullish on Cytokinetics (CYTK) following positive trial results
December 28, 2023 7:55 AM ESTCytokinetics (NASDAQ: CYTK) shares surged more than 82% Wednesday on the back of the positive results from its experimental heart treatment study.
Cytokinetics revealed that in a key Phase 3 study, its drug, Aficamten, "significantly improved exercise capacity compared to placebo." Here's how Wall Street analysts reacted to the news:
Barclays analyst Carter Gould raised the firm's price target for CYTK to $100 per share... More
